Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024.
The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas.
Quick Take on Recent Acquisitions & Deals
Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology.
The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio.
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.
BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028.
Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.
While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed.
Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.
M&A in Focus in 2025
Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky.
In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio.
Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree.
Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio.
Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease.
In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.
Potential Deals
We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies.
These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
36 minutes ago
- Globe and Mail
Dune Acquisition Corporation II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing June 12, 2025
New York, NY, June 09, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (Nasdaq: IPODU) (the 'Company') today announced that, commencing June 12, 2025, holders of the units sold in the Company's initial public offering may elect to separately trade shares of the Company's Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on The Nasdaq Stock Market under the symbols 'IPOD' and 'IPODW,' respectively. Those units not separated will continue to trade on The Nasdaq Stock Market under the symbol 'IPODU.' Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants. Dune Acquisition Corporation II was founded by its Chief Executive Officer, Carter Glatt. The Company is a blank check company whose business purpose is to effect a merger, amalgamation, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any industry or geographic region, the Company intends to focus its search for an initial business combination on companies within the software as a service, artificial intelligence, medtech or asset management and consultancy sectors. Clear Street acted as sole book-runner of the offering. The offering was made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th Floor, New York, NY 10007, by email at ecm@ or from the SEC website at A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the 'SEC') on May 6, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the search for an initial business combination. No assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the initial public offering filed with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact
CBC
an hour ago
- CBC
Warner Bros. Discovery to split into 2 companies
Social Sharing Warner Bros. Discovery said it would split into two publicly traded companies, separating its studios and streaming business from its fading cable television networks as the parent company of HBO and CNN looks to improve competition in the streaming era. The breakup is the latest unravelling of decades of media consolidation that created global conglomerates spanning content creation, distribution and in some cases, telecommunications. It unwinds WarnerMedia and Discovery's prior merger in 2022, aiming to grow the streaming and studios business without the declining networks unit weighing them down. The new streaming-and-studios company will include Warner Bros., DC Studios and HBO Max — the crown jewels of Warner Bros. Discovery's entertainment library. The networks unit, which will hold up to a 20 per cent stake in its counterpart, will house CNN, TNT Sports and Bleacher Report. CEO David Zaslav will lead the streaming and studios unit, while CFO Gunnar Wiedenfels will head the networks unit. The separation will be structured as a tax-free transaction and is expected to be completed by mid-2026. "We've continued to analyze how our industry is evolving," Zaslav told investors. "The right path forward became increasingly clear … to separate global networks and streaming and studios into two independent, publicly traded companies." Most of the company's debt would be held by the global networks company. Warner Bros. Discovery had gross debt of $38 billion US as of March. The company said it secured a $17.5 billion US bridge loan from J.P. Morgan that it would use to restructure its debt. Shares were down almost three per cent at midday, after rising by as much as 13 per cent in the hours after the announcement. Stock down since merger Warner Bros. Discovery's stock remains down nearly 60 per cent since the merger, hurt by cable subscriber loss, tough streaming competition and investor concerns over the debt-laden company's direction. Brian Wieser, CEO of Madison and Wall, an advisory firm for media, technology and other companies, said the split will not fix underlying weakness at Warner Bros. Discovery. If anything, Wieser said, it "could make them worse off by favouring financial engineering over focusing on improving existing operations or pursuing new opportunities for growth … a deal like this can hamstring both sides of the company until the transactions are closed." Media executives had initially anticipated a wave of consolidation under U.S. President Donald Trump's administration, though that has not come to pass. "For a series of reasons, that proved harder than anyone thought," said Jonathan Miller, a veteran media executive who now serves as chief executive of Integrated Media. "It looks like the characteristic of this year will be how do we get our house in order, and do what we can that's under our control." Comcast is spinning off most of its NBCUniversal cable networks portfolio into a separate company, Versant. Lions Gate Entertainment completed the separation of its Starz cable network from its film and television studio in May. Such breaking up of media conglomerates could set the stage for further deal-making, said one veteran media executive who spoke on condition of anonymity. Last week, about 59 per cent of Warner Bros. Discovery shareholders at the annual meeting voted against executive pay packages, including Zaslav's $51.9 million US 2024 compensation, in an advisory vote that signaled dissatisfaction. Like other entertainment companies, Warner Bros. Discovery is struggling with declining ratings and revenue at its cable networks. Consumers have been dropping pay-television subscriptions in favour of streaming services.
Globe and Mail
an hour ago
- Globe and Mail
Orange County Bancorp, Inc. Announces Closing of Overallotment Option and Issuance of 258,064 Shares of Common Stock
MIDDLETOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Orange County Bancorp, Inc. (the 'Company' - Nasdaq: OBT), parent company of Orange Bank & Trust Company, (the 'Bank') and Hudson Valley Investment Advisors, Inc. ('HVIA'), today announced that the underwriters for its recently completed public offering have exercised their overallotment option and completed the sale of an additional 258,064 shares of common stock at the public offering price of $23.25 per share. The expected proceeds to the Company in connection with the exercise of the option and the issuance of the additional shares, after deducting the underwriting discount and commissions but before deducting other expenses payable by the Company, are approximately $5.7 million. Piper Sandler & Co. and Stephens Inc. served as joint book-running managers. The offering was made only by means of an effective shelf registration statement on Form S-3 (File No. 333-280793), including a preliminary prospectus supplement and final prospectus supplement, copies of which may be obtained for free by visiting EDGAR on the SEC website at Additionally, copies may be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by phone at 1-800-747-3924, or by email at prospectus@ or Stephens Inc., 111 Center Street, Little Rock, AR 72201, or by phone at 1-800-643-9691. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Orange County Bancorp, Inc. Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company and Hudson Valley Investment Advisors, Inc. Orange Bank & Trust Company is an independent bank that began with the vision of 14 founders over 125 years ago. It has grown through innovation and an unwavering commitment to its community and business clientele to approximately $2.6 billion in total assets. Hudson Valley Investment Advisors, Inc. is a Registered Investment Advisor in Goshen, NY. It was founded in 1996 and acquired by the Company in 2012. Forward-Looking Statements The information disclosed in this press release includes various forward-looking statements that are made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words 'anticipates,' 'projects,' 'intends,' 'estimates,' 'expects,' 'believes,' 'plans,' 'may,' 'will,' 'should,' 'could,' and other similar expressions are intended to identify such forward-looking statements. The Company cautions that these forward-looking statements are necessarily speculative and speak only as of the date made, and are subject to numerous assumptions, risks and uncertainties, all of which may change over time. Actual results could differ materially from such forward-looking statements. Accordingly, you should not place undue reliance on forward-looking statements. In addition to the specific risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the following factors, among others, could cause actual results to differ materially and adversely from such forward-looking statements: those related to the real estate and economic environment, particularly in the market areas in which the Company operates, competitive products and pricing, fiscal and monetary policies of the U.S. Government, inflation, changes in government regulations affecting financial institutions, including regulatory fees and capital requirements, changes in prevailing interest rates, tariffs, increased levels of loan delinquencies, problem assets and foreclosures, credit risk management, asset-liability management, cybersecurity risks, geopolitical conflicts, public health issues, the financial and securities markets and the availability of and costs associated with sources of liquidity. The Company does not undertake and specifically declines any obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
